{"id":910456,"date":"2025-11-14T19:59:19","date_gmt":"2025-11-15T00:59:19","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-ademi-firm-investigates-whether-repare-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\/"},"modified":"2025-11-14T19:59:19","modified_gmt":"2025-11-15T00:59:19","slug":"shareholder-alert-the-ademi-firm-investigates-whether-repare-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-ademi-firm-investigates-whether-repare-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\/","title":{"rendered":"Shareholder Alert: The Ademi Firm investigates whether Repare Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">MILWAUKEE<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Nov. 14, 2025<\/span><\/span> \/PRNewswire\/ &#8212; The Ademi Firm is investigating Repare (Nasdaq: RPTX) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with XenoTherapeutics, Inc.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/2672539\/Ademi_Fruchter__Logo.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/2672539\/Ademi_Fruchter__Logo.jpg\" title=\"Ademi &amp; Fruchter Logo (PRNewsfoto\/Ademi LLP)\" alt=\"Ademi &amp; Fruchter Logo (PRNewsfoto\/Ademi LLP)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>Click <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4559295-1&amp;h=1371030042&amp;u=https%3A%2F%2Fwww.ademilaw.com%2Fcase%2Frepare-therapeutics-inc%2F&amp;a=here\" target=\"_blank\" rel=\"nofollow\">here<\/a> to learn how to join our investigation and obtain additional information or contact us at <a href=\"mailto:gademi@ademilaw.com\" target=\"_blank\" rel=\"nofollow\">gademi@ademilaw.com<\/a> or toll-free: 866-264-3995. There is no cost or obligation to you.<\/p>\n<p>In the transaction, Repare shareholders will receive an estimated <span class=\"xn-money\">$1.82<\/span> per share in cash at closing, based on the company&#8217;s current estimates. The final payment amount will be determined by Repare&#8217;s cash balance at closing after deducting transaction costs and outstanding liabilities. Additionally, shareholders will receive one non-transferable contingent value right (CVR) per share, entitling them to portions of future proceeds from existing partnerships and potential asset dispositions. The CVRs provide varying percentages of net proceeds from partnerships with Bristol-Myers Squibb, Debiopharm and DCx Biotherapeutics, ranging from 90% to 75% depending on timing over a 10-year period.<\/p>\n<p>Repare insiders will receive substantial benefits as part of change of control arrangements.<\/p>\n<p>The transaction agreement unreasonably limits competing transactions for Repare by imposing a significant penalty if Repare accepts a competing bid. We are investigating the conduct of the Repare board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.<\/p>\n<p>We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.<\/p>\n<p>Contacts<\/p>\n<p>Ademi &amp; Fruchter LLP <br \/><span class=\"xn-person\">Guri Ademi<\/span><br \/>Toll Free: (866) 264-3995<br \/>Fax: (414) 482-8001<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=CG25415&amp;sd=2025-11-14\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/shareholder-alert-the-ademi-firm-investigates-whether-repare-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders-302616105.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/shareholder-alert-the-ademi-firm-investigates-whether-repare-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders-302616105.html<\/a><\/p>\n<p>SOURCE  Ademi LLP<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=CG25415&amp;Transmission_Id=202511141956PR_NEWS_USPR_____CG25415&amp;DateId=20251114\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire MILWAUKEE , Nov. 14, 2025 \/PRNewswire\/ &#8212; The Ademi Firm is investigating Repare (Nasdaq: RPTX) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with XenoTherapeutics, Inc. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, Repare shareholders will receive an estimated $1.82 per share in cash at closing, based on the company&#8217;s current estimates. The final payment amount will be determined by Repare&#8217;s cash balance at closing after deducting transaction costs and outstanding liabilities. Additionally, shareholders will receive one non-transferable contingent value right (CVR) per share, entitling &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-ademi-firm-investigates-whether-repare-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Shareholder Alert: The Ademi Firm investigates whether Repare Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-910456","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Shareholder Alert: The Ademi Firm investigates whether Repare Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-ademi-firm-investigates-whether-repare-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shareholder Alert: The Ademi Firm investigates whether Repare Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire MILWAUKEE , Nov. 14, 2025 \/PRNewswire\/ &#8212; The Ademi Firm is investigating Repare (Nasdaq: RPTX) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with XenoTherapeutics, Inc. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, Repare shareholders will receive an estimated $1.82 per share in cash at closing, based on the company&#8217;s current estimates. The final payment amount will be determined by Repare&#8217;s cash balance at closing after deducting transaction costs and outstanding liabilities. Additionally, shareholders will receive one non-transferable contingent value right (CVR) per share, entitling &hellip; Continue reading &quot;Shareholder Alert: The Ademi Firm investigates whether Repare Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-ademi-firm-investigates-whether-repare-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-15T00:59:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/2672539\/Ademi_Fruchter__Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-ademi-firm-investigates-whether-repare-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-ademi-firm-investigates-whether-repare-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Shareholder Alert: The Ademi Firm investigates whether Repare Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders\",\"datePublished\":\"2025-11-15T00:59:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-ademi-firm-investigates-whether-repare-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\\\/\"},\"wordCount\":291,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-ademi-firm-investigates-whether-repare-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2672539\\\/Ademi_Fruchter__Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-ademi-firm-investigates-whether-repare-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-ademi-firm-investigates-whether-repare-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\\\/\",\"name\":\"Shareholder Alert: The Ademi Firm investigates whether Repare Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-ademi-firm-investigates-whether-repare-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-ademi-firm-investigates-whether-repare-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2672539\\\/Ademi_Fruchter__Logo.jpg\",\"datePublished\":\"2025-11-15T00:59:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-ademi-firm-investigates-whether-repare-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-ademi-firm-investigates-whether-repare-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-ademi-firm-investigates-whether-repare-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2672539\\\/Ademi_Fruchter__Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2672539\\\/Ademi_Fruchter__Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-ademi-firm-investigates-whether-repare-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shareholder Alert: The Ademi Firm investigates whether Repare Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Shareholder Alert: The Ademi Firm investigates whether Repare Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-ademi-firm-investigates-whether-repare-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\/","og_locale":"en_US","og_type":"article","og_title":"Shareholder Alert: The Ademi Firm investigates whether Repare Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders - Market Newsdesk","og_description":"PR Newswire MILWAUKEE , Nov. 14, 2025 \/PRNewswire\/ &#8212; The Ademi Firm is investigating Repare (Nasdaq: RPTX) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with XenoTherapeutics, Inc. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, Repare shareholders will receive an estimated $1.82 per share in cash at closing, based on the company&#8217;s current estimates. The final payment amount will be determined by Repare&#8217;s cash balance at closing after deducting transaction costs and outstanding liabilities. Additionally, shareholders will receive one non-transferable contingent value right (CVR) per share, entitling &hellip; Continue reading \"Shareholder Alert: The Ademi Firm investigates whether Repare Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-ademi-firm-investigates-whether-repare-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-15T00:59:19+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/2672539\/Ademi_Fruchter__Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-ademi-firm-investigates-whether-repare-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-ademi-firm-investigates-whether-repare-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Shareholder Alert: The Ademi Firm investigates whether Repare Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders","datePublished":"2025-11-15T00:59:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-ademi-firm-investigates-whether-repare-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\/"},"wordCount":291,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-ademi-firm-investigates-whether-repare-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2672539\/Ademi_Fruchter__Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-ademi-firm-investigates-whether-repare-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-ademi-firm-investigates-whether-repare-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\/","name":"Shareholder Alert: The Ademi Firm investigates whether Repare Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-ademi-firm-investigates-whether-repare-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-ademi-firm-investigates-whether-repare-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2672539\/Ademi_Fruchter__Logo.jpg","datePublished":"2025-11-15T00:59:19+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-ademi-firm-investigates-whether-repare-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-ademi-firm-investigates-whether-repare-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-ademi-firm-investigates-whether-repare-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/2672539\/Ademi_Fruchter__Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/2672539\/Ademi_Fruchter__Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-ademi-firm-investigates-whether-repare-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Shareholder Alert: The Ademi Firm investigates whether Repare Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/910456","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=910456"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/910456\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=910456"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=910456"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=910456"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}